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Impaired wound healing and ulceration represent a serious complication of both type 1 and type 2 diabetes. Cytoskeletal protein
Flightless I (Flii) is an important inhibitor of wound repair, and reduced Flii gene expression in fibroblasts increased migration,
proliferation, and adhesion. As such it has the ability to influence all phases of wound healing including inflammation, remodelling
and angiogenesis. Flii has the potential to modulate inflammation through its interaction with MyD88 which it an adaptor protein
for TLR4. To assess the effect of Flii on the inflammatory response of diabetic wounds, we used a murine model of streptozocin-
induced diabetes and Flii genetic mice. Increased levels of Flii were detected in Flii transgenic murine wounds resulting in impaired
healing which was exacerbated when diabetes was induced.When Flii levels were reduced in diabetic wounds of Flii-deficient mice,
healing was improved and decreased levels of TLR4were observed. In contrast, increasing the level of Flii in diabeticmouse wounds
led to increased TLR4 and NF-𝜅B production. Treatment of murine diabetic wounds with neutralising antibodies to Flii led to an
improvement in healing with decreased expression of TLR4. Decreasing the level of Flii in diabetic wounds may therefore reduce
the inflammatory response and improve healing.
1. Introduction
Up to 25% of people with diabetes can expect to develop
a foot ulcer at some point in their lives [1]. Due to poor
outcomes of existing therapies, lower extremity amputation
is a common complication, affecting 15% of diabetics with
foot ulcers, with one major amputation occurring every 30
seconds worldwide and over 2500 limbs lost a day [2]. The
effectiveness of current treatments for diabetic foot ulcers is
limited, and many patients with chronic, unhealed wounds
need continual care. Understanding the processes involved in
impaired wound healing will help to develop new therapeutic
targets and tools for improving wound repair.
One area of research which has been shown to be
integral to the wound repair process is that of the actin
cytoskeleton which is a filamentous network found in all cells
and facilitates processes such as cellular adhesion, migration
and contraction [3, 4]. Onemember of the actin cytoskeleton
is Flightless I (Flii) which is a member of the gelsolin family
of actin remodelling proteins [5]. Flii colocalizes with actin
and microtubule-based structures, is required for normal
actin distribution, and possesses Ca2+-independent G-actin
binding activity as well as F-actin binding and severing
activities [3, 6–8]. In addition to its role as a regulator
of the cytoskeleton, the LRR domain allows Flii to bind a
number of other proteins unrelated to actin including LRR
Flii interacting proteins 1 and 2 (LLRFIP1 and LRRFIP2)
and the double-stranded RNA binding protein TRIP [4, 9].
Flii is involved in numerous cellular activities including
regulating transcription via coactivation of nuclear hormone
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receptors [10, 11] and regulation of beta-catenin-dependent
transcription [12], important signalling pathways including
the TLR pathway [13, 14], cellular polarity, asymmetric cell
division [15], proliferation via interactions with calmodulin-
dependent protein kinase type II [16], and inflammation
and cytokine production via caspase activation and IL-1𝛽
maturation [17]. Flii-deficient mice have improved reepithe-
lialisation after wounding while Flii overexpressing mice
have impaired healing with larger wounds with reduced con-
traction, cellular proliferation and delayed reepithelialisation
[18].
Increased inflammation is an important contributing
factor in the failure to heal of diabetic foot ulcers [19].
Inflammation is an integral part of the wound healing process
and is regulated by toll-like receptors (TLRs). TLRs are
key innate immune receptors that alert the immune system
to tissue damage and mediate the inflammatory response.
The human TLR family consists of 10 members structurally
characterised by the presence of a leucine-rich repeat (LRR)
domain in their extracellular domain and toll/interleukin-
(IL-) 1 receptor (TIR) domain, in their intracellular domain.
Through their intracellular TIR domain TLRs activate or
deactivate signalling pathways that generate cytokine and
chemokine production and thereby regulate inflammatory
responses. TLR signalling is tightly regulated to control
the intensity and duration of inflammation [12]. TLRs are
expressed on a wide variety of cells including macrophages
and neutrophils, and they respond to an array of viral,
bacterial, and fungal ligands as well as cellular debris [13].
The receptors convey their specificity through the utilization
of different adaptor proteins such as myeloid differentiation
factor 88 (MyD88), TIR-associated protein (TIRAP), TIR
domain containing adaptor protein-inducing IFN-𝛽 (TRIF),
and TRIF-related adaptor molecule (TRAM) [13–15]. Upon
activation, the adaptor proteins promote signalling to result
in the expression of proinflammatory cytokines, growth
factors, and interferons. MyD88 has been shown to play an
important role during wound healing as MyD88 knockout
mice have impaired wound healing [16] with wounds show-
ing reduced contraction, decreased and delayed granulation
tissue formation, and reduced blood vessel density [16].
The LRR region of Flii shares 29% sequence identity and
42% similarity to TLR4 [20]. Through its interaction with
MyD88, it has been suggested that Flii can modulate inflam-
mation by suppressing TLR4-MyD88-mediated activation of
NF-𝜅B [21]. Conversely, a reduction in the Flii level may
enhance activation of NF-𝜅B and increase cytokine secretion
[20]. Several studies investigating the effect of Flii on TLR
signalling in murine macrophages suggest that Flii can
sequester activator proteins such as LPS and adaptor proteins
such as MyD88 resulting in reduced cytokine expression
[10, 11, 16, 17]. In this study we used mice with low (Flii+/−),
normal (WT), and high (FliiTg/Tg) Flii gene expression
levels to investigate the function of Flii in a murine wound
healing model of streptozocin-induced type 1 diabetes. We
also investigated whether modulation of Flii by exogenous
application of Flii neutralising antibodies improved diabetic
wound healing via effects on TLR-mediated inflammation.
2. Materials and Methods
2.1. Antibodies. Mouse monoclonal anti-Flii antibodies
raised to the LRR domain of the human Flii protein and
the rabbit anti-human MyD88 antibody were obtained
from Santa Cruz Biotechnology (VIC, Australia). Rabbit
anti-human TLR4 and TLR9 antibodies were obtained from
Imgenex (SA, Australia), mouse anti-human CD14 antibody
and mouse anti-human CD16 antibody from BD Biosciences
(NSW, Australia), and rabbit anti-human NF-𝜅B antibody
from Abcam (NSW, Australia). All antibodies were used
at a 1 : 100 dilution. The appropriate secondary antibodies
were used depending on the fluorescence required—goat
anti-mouse Alexa Fluor 488 and goat anti-mouse Alexa
Fluor 594 were obtained from Life Technologies (VIC,
Australia) and also used at a 1 : 100 dilution. Flii is a highly
conserved protein with 95% homology between mice and
humans [19]. The Flii neutralising antibodies (FnAbs) used
in in vivo diabetic mouse trials were mouse monoclonal
anti-Flii antibodies raised against the N-terminus of the LRR
domain of the human Flii protein [22] and obtained from
Monoclonal Antibody SA Technologies (SA, Australia).
Mouse IgG antibody used as a control in vivo diabetic mouse
was obtained from Sigma (MO, USA)
2.2. Animal Studies. All experiments were approved by the
Women’s and Children’s Health Network Animal Ethics
Committee following the Australian Code of Practice for
the Care and the Use of Animals for Scientific Purposes.
Studies were performed using mice with a BALB/c back-
ground. Three strains of mice were used in this study with
low (Flii+/−), normal (WT), and high (FliiTg/Tg) Flii gene
expression levels. Mice lacking one copy of the Flii gene, the
double knockout being embryonically lethal [23], were made
as described previously [23] and will be written as Flii+/−.
Transgenicmice carrying two extra copies of human Flii gene
incorporated into mouse genome will be written as FliiTg/Tg.
2.3. Murine Model of Diabetic Wound Healing. Six female
Flii+/−, WT, and FliiTg/Tg mice of 12–16 weeks of age and
weighing 20–35 g were used for the induction of diabetes.
Streptozocin (STZ) was used to induce type 1 diabetes
(Sigma-Aldrich, MO, USA). STZ is toxic to the pancreatic
beta-islet cells, rendering the mouse unable to produce ade-
quate amount of insulin. Mice were given one intraperitoneal
(IP) injection of STZ for 5 consecutive days (STZ: 50mg/kg)
in citrate buffer of pH 6.5. This dose was chosen based on
previously reported studies [24]. Age-matched nondiabetic
control animals were treated with an equivalent dose of vehi-
cle (citrate buffer alone). Diabetic symptoms were observed
closely, and nonfasting blood glucose levels (BGLs) were
tested weekly by tail vein sampling. To maintain body weight
and prevent ketoacidosis, animals with confirmed diabetes
weremaintainedwith subcutaneous injection of insulin (1 IU,
Mixtard 30/70, Novo-Nordisk, NSW, Australia). Mice were
tested for sufficient levels of hyperglycaemia at 6 weeks after
BioMed Research International 3
the last STZ injection, and only those with blood glucose lev-
els greater than 15mmol/L were wounded. Diabetic animals
were wounded using a 6mm biopsy punch (Stiefel Laborato-
ries, NSW, Australia). Anaesthesia was induced by inhalation
of isoflurane (5% induction at 2 L/min and 2% maintenance
at 500mL/min). To expose the skin, hair was removed by
shaving and then application of hair removal cream (Veet,
Reckitt Benckiser, NSW, Australia). Two 6mm full thickness
wounds, one on each side of the midline, were created on the
dorsum of the mouse. Temgesic (buprenorphine 0.05mg/kg)
was administered post-operatively to provide analgesia for
up to 8 hours. The mice were euthanized at 7 days following
wounding. Digital photographs of the wounds were taken at
0 and 7 days after wounding. A ruler was aligned next to the
wound to allow direct wound areameasurements to bemade.
Wounds were fixed in formalin and processed for histology
and immunohistochemistry.
An additional cohort of female WT diabetic mice were
injected intradermally around the wound margins with
200𝜇L of FnAb (50 𝜇g/mL; 𝑛 = 10) or mouse IgG control
(50𝜇g/mL; 𝑛 = 10) immediately after surgery and at 1
and 2 days after wounding. Digital photographs of wounds
were taken at days 0 and 7 after wounding. All animals
were euthanized at day 7 post-wounding with the wounds
harvested, fixed in formalin, and processed for histological
analysis.
2.4. Histology, Immunohistochemistry, and Image Analysis.
Histological sections (4𝜇m) of mouse wounds were cut
and stained with haematoxylin and eosin or subjected
to immunohistochemistry following antigen retrieval as
described previously [25]. Briefly, following antigen retrieval,
sections were blocked in 3% normal goat serum, pri-
mary antibodies against Flii (1 : 100), TLR9 (1 : 100), TLR4
(1 : 100), MyD88 (1 : 100) and NF-𝜅B (1 : 100) were applied and
incubated overnight at 4∘C. Appropriate Alexa Fluor 488-
conjugated secondary antibodies (1 : 100) were used and incu-
bated for 1 hour. Fluorescence intensity was determined using
AnalySIS software package (Soft Imaging System GmbH,
Munster, Germany), and optical fluorescence in the epider-
mis and dermis of the wounds was analysed as previously
described [25]. Negative controls included replacing primary
antibodies with normalmouse or normal rabbit IgG. Primary
or secondary antibodies were omitted to verify the staining
and detect nonspecific binding. All control sections had
negligible immunofluorescence.
2.5. Histological Image Analysis. Histological image analysis
was performed using the Digital Microscope Camera Pro-
gRes C5 (JENOPTIK Laser, Jena, Germany). Wound size
was determined by manually drawing below the clot or the
portions of the wound that were not covered by epidermis.
Dermal wound gape was determined by measuring between
the dermal wound margins. Fluorescent images were taken
using an Olympus IX81 (Olympus Australia, Melbourne,
VIC, Australia) at a magnification of ×20. The fluorescent
intensity of the staining was calculated using Image Pro-Plus
software (Media Cybernetics, MD, USA).
2.6. Statistical Analysis. Statistical significancewas calculated
using a paired Students t-test or analysis of variance. A 𝑃
value of 0.05 or less was considered significant.
3. Results
3.1. Diabetic Wounds Heal Faster in Mice with Low Levels of
Flii Gene Expression. To assess the biological function of Flii
and determine the effect of Flii gene modulation on diabetic
wound healing, three lines of mice were used expressing low
(Flii+/−), normal (Flii+/+), and high (FliiTg/Tg) levels of Flii.
Representative digital images of wounds at 7 days subsequent
to wounding are shown in Figure 1(A). Overexpression of
Flii in diabetic and nondiabetic wounds resulted in delayed
wound closure at day 7 following wounding (Figure 1(A)).
In contrast, wound area was decreased significantly when Flii
levels were reduced (Flii+/−; 𝑃 = 0.01) compared to FliiTg/Tg
mice at day 7 following wounding (Figure 1(B)(a)). Repre-
sentative microscopic images of day 7 wounds are shown in
Figure 1(A). Histological assessment of these diabetic mouse
wounds showed that at day 7 the dermal wound gape was
significantly smaller in Flii-deficient mice (Flii+/−) compared
with Flii overexpressing (FliiTg/Tg) mice (Figure 1(B)(b); 𝑃 =
0.05).
3.2. Treatment of Diabetic Wounds with Flii Neutralising Anti-
bodies (FnAbs) Improves Wound Healing. Previous studies
have shown that intradermal injection of Flii neutralising
antibodies reduces the level of Flii in wounds and improves
healing [26]. FnAbs were injected intradermally at days
0, 1, and 2, and representative images of macroscopic (at
days 0 and 7) and microscopic (day 7) appearances of
diabetic wounds are shown in Figure 2(A). Intradermal
administration of FnAb to diabetic wounds resulted in a 1.9-
fold decrease in average wound area (Figure 2 (B)(a)) and
histological wound gape (Figure 2(B)(b)) compared to IgG-
treated WT diabetic controls (Figure 2(B) (a) and (b); P ≤
0.05; IgG versus FnAb).
3.3. Elevating Flii Gene Expression Increases TLR4 in Dia-
betic Mouse Wounds. Immunofluorescence staining of day
7 diabetic wounds in Flii+/−, WT, and FliiTg/Tg mice shows
increased Flii in FliiTg/Tg diabetic wounds > WT > Flii+/−
wounds (Figure 3(A)) with significantly less Flii staining
being observed in day 7 diabetic Flii+/− and WT wounds
(𝑃 = 0.04; Flii+/− versus FliiTg/Tg; 𝑃 = 0.05; WT versus
FliiTg/Tg; Figure 3(B)(a)). The presence of foreign molecules
and pathogens was detected by a family of receptors known
as toll-like receptors (TLRs), which contribute to prolonged
inflammation [27]. To assess if altered levels of Flii affected
TLR4 expression, diabetic wounds were stained for TLR4.
Increasing Flii leads to a concomitant increase in TLR4
expression (Figure 3(A)(d)–(f)). Flii deficiency caused a
significant reduction in TLR4 expression (Figure 3(B)(b))
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Figure 1: Flii delays wound healing in diabetic murine wounds after 7 days.(A) Macroscopic images of day 7 nondiabetic and diabetic mouse
wounds in the Flii +/−, WT, and FliiTg/Tg mice and representative histological H&E staining of day 7 diabetic wounds. Scale bars = 1mm for
macroscopic pictures, and for the histology magnification was ×4 and scale bars = 100 𝜇m. (B) shows graphical representations of the wound
areas of the day 7 (a) wound areas of the three Flii genotype diabetic wounds (𝑛 = 6) and (b) the microscopic dermal wound gape of the day
7 diabetic wounds where ∗∗P ≤ 0.01 and ∗P ≤ 0.05 (𝑛 = 6).
at day 7 following wounding which was significantly lower
than WT and FliiTg/Tg wounds (P ≤ 0.01 WT versus Flii+/−;
𝑃 ≤ 0.001WT versus FliiTg/Tg). Given that the inflammatory
response in diabetic wounds was associated with increased
TLR4 expression,wenext proceeded to test if the downstream
molecule NF-𝜅B production was also affected. Figure 3(A)
shows that NF-𝜅B expression was also increased in Flii over-
expressing wounds (5-fold higher thanWT diabetic wounds)
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Figure 2: Healing can be improved by the application of Flii neutralizing antibodies. (A) shows macroscopic images of day 0 and day 7
excisional WT diabetic wounds treated with IgG isotype control (𝑛 = 10) and Flii neutralizing antibody (FnAb) (𝑛 = 10). Representative
pictures of H&E staining of day 7 diabetic wounds treated with IgG and FnAb. (B) Graphical representation of the (a) wound areas and (b)
histological wound gapes of the days 0 and 7 IgG control-treated and FnAb-treated WT diabetic wounds where ∗P ≤ 0.05 (𝑛 = 10).
(Figure 3(B)(c); P ≤ 0.001 FliiTg/Tg versus WT). A reduction
in NF-𝜅B was observed between Flii+/− wounds andWT, but
this was not statistically significant (Figure 3(B)(c)).
3.4. Flii Neutralising Antibodies Reduce TLR4 Expression
in Diabetic Wounds. Given that intradermal application of
FnAb resulted in improved healing of diabetic wounds
(Figure 2(A)), we proceeded to test whether this was in part
due to modulated levels of TLR4-mediated inflammation.
TLR4 and NF-𝜅B expression was quantified, and represen-
tative images are shown in Figure 4(A). Treatment with
FnAbs resulted in a significant decrease in TLR4 expression
(Figure 4(B); P ≤ 0.05 IgG versus FnAb) whereas NF-
𝜅B expression in day 7 FnAb-treated wounds remained
unchanged compared to IgG controls (Figure 4(B)(b)).
6 BioMed Research International
Flii+/− WT FliiTg/Tg
(a) )c()b(
)e()d( (f)
)i()h()g(
Flii
TLR4
(A)
0
500
1000
1500
2000
2500
0
50
100
150
200
250
300
(b)(a)
0
50
100
150
200
250
4RLTiilF
(c)
Flii+/− WT FliiTg/Tg Flii+/− WT FliiTg/Tg Flii+/− WT FliiTg/Tg
Fl
ii 
flu
or
es
ce
nc
e i
nt
en
sit
y
TL
R4
 fl
uo
re
sc
en
ce
 in
te
ns
ity
∗∗∗∗∗∗
∗∗
∗
(B)
NF-𝜅B
NF-𝜅B
N
F-
𝜅
B 
flu
or
es
ce
nc
e i
nt
en
sit
y
Figure 3: Concomitant increase in TLR4 and NF-𝜅B staining occurs with increasing levels of Flii. (A) Representative images for Flii (a)–(c),
TLR4 (d)–(f), and NF-𝜅B (g)–(i) immunostaining of the three Flii genotypes (Flii+/−, WT, and FliiTg/Tg). (B) Graphical representation of (a)
Flii, (b) TLR4, and (c) NF-𝜅B in Flii+/−, WT, and FliiTg/Tg day 7 diabetic wounds. ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001 (𝑛 = 6) and scale bar =
100𝜇m.
4. Discussion
Flii has been identified as a protein that can inhibit the rate
of healing by reducing the migration of keratinocytes and
fibroblasts and limiting the degree of wound contraction
[18, 22, 28]. Flii deficiency is associated with improved reep-
ithelialisation in acute wounds [18] while Flii overexpressing
mice have impaired wound healing with delayed reepithe-
lialisation. Here we have investigated if Flii is involved
in the impaired healing associated with diabetic wounds.
Wound healing was impaired as Flii levels increased, and
this impairment was exacerbated when diabetes was induced.
Flii is upregulated during the wound repair process [18, 25]
and is constitutively secreted by two of the major cell types
found in wounds: fibroblasts and macrophages in response
to wounding both in vitro [29] and in vivo [22, 30]. Recent
studies show that Flii is also secreted through a nonclassical
late endocytic/lysosomal pathway of secretion by fibroblasts
and macrophages [29]. Addition of Flii monoclonal neutral-
ising antibodies as a means of reducing the Flii protein in
the wound environment was able to counteract the negative
effect of Flii on wound healing [18], and treatment of murine
diabetic wounds with neutralising antibodies to Flii led to an
improvement in healing suggesting that high levels of Flii in
diabetic wounds contribute to wound chronicity.
Inflammation is an essential component of the normal
wound healing process; however excessive inflammation is
detrimental to this process [31]. Disproportionate inflamma-
tion is one of the major contributing factors to the formation
of diabetic ulcers as these chronic wounds often have an
unregulated and excessive inflammatory reaction [31, 32].
The innate immune system detects foreign particles such as
BioMed Research International 7
IgG FnAb
w
e
w
e
w e
w e
NF-𝜅B
TLR4
0
10
20
30
40
50
60
70
IgG FnAb IgG FnAb
TL
R4
 fl
uo
re
sc
en
ce
 in
te
ns
ity
TLR4
0
5
10
15
20
25
30
35
40
45
(b)(a)
NF-𝜅B
N
F-
𝜅
B 
flu
or
es
ce
nc
e i
nt
en
sit
y
∗
(A)
(B)
Figure 4: Modulation of Flii by exogenous application of Flii neutralising antibodies (FnAbs) reduces TLR4 expression in diabetic wounds.
(A) Representative images of TLR4 and NF-𝜅B staining of day 7 diabetic wounds treated with IgG and FnAb. (B) Graphical representation of
(a) TLR4 and (b) NF-𝜅B staining of day 7 diabetic wounds treated with IgG and FnAb. ∗P ≤ 0.05.
bacteria, fungi, and viruses via pathogen-associated molec-
ular pattern (PAMP) molecules leading to the activation
of the inflammatory response via toll-like receptors (TLRs)
which recognise PAMPs [33, 34]. TLRs have also been linked
to diabetes with studies showing that TLR-immune activa-
tion can result in activation of proinflammatory pathways
leading to autoimmunity which may cause the onset of
diabetes [27]. Previous reports suggested that stimulation of
TLR4 leads to activation of the downstream transcriptional
regulator NF-𝜅B resulting in cytokine secretion [21], and
both TLR4 expression and pro-inflammatory cytokine NF-
𝜅Bwere elevated in themurine diabetic wounds which would
further contribute to inflammation and chronicity. In Flii-
deficient diabetic mouse wounds, decreased TLR4 and NF-
𝜅B were observed and when Flii neutralising antibodies were
administered to diabetic wounds, a decrease in TLR4 expres-
sion was seen suggesting a dampening of the inflammatory
response when Flii levels were reduced. Interestingly, the
effect of FnAb was specific to TLR4 and did not appear to
affect the production of the proinflammatory cytokine NF-
𝜅B suggesting that alternative pathways may still be active in
these wounds.
In vitro studies have previously shown that the LRR region
of Flii shares 29% sequence identity and 42% similarity to
TLR4 [20] suggesting that Flii may influence TLR signalling.
However, while in vitro studies showed that through its
interaction with MyD88, Flii was able to negatively regulate
the TLR4-MyD88-mediated activation of NF-𝜅B and the
subsequent cytokine secretion in macrophages [20, 21], our
studies show that in vivo, in mouse diabetic wounds the
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increased levels of Flii appear to correlate with an increase
in the expression of TLR4 and its signalling protein NF-𝜅B.
This is clearly in opposition to the findings in these cell-based
studies but may be accounted for by the differing in vivo and
in vitro environments.The time points investigated also differ
with the in vitro studies looking at responses from 3 to 6 hours
whereas this wounding study investigated time points which
were measured in days rather than hours. It is, however, not
inconceivable that Flii may have a dual role in wounding and
in the inflammatory response which depends on the time
point investigated.
In conclusion, inflammation is an integral component
of the normal wound healing process and occurs even in
the absence of infection; however excessive and prolonged
inflammation impairs healing. Flii is a multifunctional pro-
tein and is currently emerging as a regulator of inflammation;
however, whether it is pro-or anti-inflammatory is still to
be determined. Our in vivo studies show that reducing the
expression of Flii in diabetic murine wounds improves heal-
ing and reduces the proinflammatory response. Being able
to manipulate the level of inflammation in a wound would
greatly improve the wound healing outcomes of patients
with diabetes, and it remains to be elucidated whether
neutralisation of Flii in human diabetic wounds could help
improve healing of these chronic nonhealing ulcers.
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